Immutep Ltd ADR
Price & Volume
Stats
See more52W Range | $1.32-$2.71 |
Market Cap | $275.9M |
Shares Short | 4M |
Financials
See moreRevenue (12 Mos) | $5M |
Revenue Growth (YoY) | 9.5% |
Gross Profit (12 Mos) | -$56.3M |
Diluted EPS | -$0.28 |
News
See moreYahoo Finance • 26 days ago
Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025
Yahoo Finance • 2 months ago
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
Yahoo Finance • 2 months ago
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
Yahoo Finance • 3 months ago
Immutep (IMMP) Announces Positive Initial Efficacy Data and Continued Favourable Safety Data
About
CEO | Mr. Marc Voigt |
CFO | Mr. Marc Voigt |
Address | Australia Square, Sydney, NSW, Australia, 2000 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 0 |
